Cytotechnology, Год журнала: 2024, Номер 76(5), С. 571 - 584
Опубликована: Июнь 24, 2024
Язык: Английский
International Journal of Gynecological Cancer, Год журнала: 2024, Номер unknown, С. ijgc - 005700
Опубликована: Авг. 28, 2024
The majority of patients with ovarian cancer relapse within 3 years first line chemotherapy. Therefore, choosing the most appropriate treatment in recurrence setting has a fundamental role defining patient's prognosis. Treatment options include systemic and intra-peritoneal chemotherapy, secondary cytoreductive surgery, stereotactic body radiotherapy. best therapeutic choice depends on multiple factors not only treatment-free interval. For therapy, prior lines residual toxicities, comorbidities, performance status, patient preferences should be taken into account. Secondary surgery can proposed which complete tumor resectability predicted those oligometastatic disease. Stereotactic radiotherapy represents valid alternative to for disease high local control minimal toxicity. Current evidence demonstrated an emerging BRCA mutational status molecular profiling impacting response treatments. these could provide guidance decision process help identify who respond better poly(ADP-ribose) polymerase (PARP)-inhibitors or immunotherapy combined approach rather than platinum-based knowledge this field widen options, especially platinum-resistant patients. In review, we offer overview state art regarding radiotherapy, their implications clinical practice process, so as tailored therapy recurrent cancer.
Язык: Английский
Процитировано
4
Diagnostics, Год журнала: 2025, Номер 15(4), С. 406 - 406
Опубликована: Фев. 7, 2025
Ovarian cancer (OC), the seventh most common in women and lethal gynecological malignancy, is a significant global health challenge, with >324,000 new cases >200,000 deaths being reported annually. OC characterized by late-stage diagnosis, poor prognosis, 5-year survival rates ranging from 93% (early stage) to 20% (advanced stage). Despite advances genomics proteomics, effective early-stage diagnostic tools population-wide screening strategies remain elusive, contributing high mortality rates. The complex pathogenesis of involves diverse histological subtypes genetic predispositions, including BRCA1/2 mutations; notably, considerable proportion have hereditary component. Current modalities, imaging techniques (transvaginal ultrasound, computed/positron emission tomography, magnetic resonance imaging) biomarkers (CA-125 human epididymis protein 4), varying degrees sensitivity specificity, limited efficacy detecting OC. Emerging technologies, such as liquid biopsy, multiomics, artificial intelligence (AI)-assisted diagnostics, may enhance early detection. Liquid biopsies using circulating tumor DNA microRNAs are popular minimally invasive tools. Integrated multiomics has advanced biomarker discovery. AI algorithms improved interpretation risk prediction. Novel methods organoids multiplex panels explored overcome current limitations. This review highlights critical need for continued research innovation reduce mortality, improve patient outcomes posits personalized medicine, integrated emerging targeted initiatives collaborative efforts, which address care access disparities promote cost-effective, scalable strategies, potential combat
Язык: Английский
Процитировано
0
European Journal of Surgical Oncology, Год журнала: 2025, Номер unknown, С. 109713 - 109713
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0
Frontiers in Oncology, Год журнала: 2024, Номер 14
Опубликована: Авг. 16, 2024
Despite advancements in cancer research, epithelial ovarian remains a leading threat to women's health with low five-year survival rate of 48%. Prognosis for advanced cases, especially International Federation Gynecology and Obstetrics (FIGO) III-IV, is poor. Standard care includes surgical resection platinum-based chemo, but 70-80% face recurrence chemoresistance. In recent years, three- dimensional (3D) models, patients-derived organoids (PDOs), have revolutionized research personalized treatment. By transcending the constraints conventional accurately recapitulate crucial morphological, histological, genetic characteristics diseases, particularly context cancer. The extensive potential explored, spanning from foundational theories cutting-edge applications. As potent preclinical offer invaluable tools predicting patient treatment responses guiding development therapeutic strategies. Furthermore, arena drug evaluation, demonstrate their unique versatility as platforms, enabling comprehensive testing innovative combinations novel candidates, thereby pioneering new avenues pharmaceutical research. Notably, mimic dynamic progression cancer, inception systemic dissemination, shedding light on intricate subtle disease mechanisms, providing insights. Operating at an individualized level, also unravel complex mechanisms underlying resistance, presenting strategic opportunities effective This review summarizes emerging role organoids, meticulously cultivated cellular clusters within three-dimensional groundbreaking paradigm
Язык: Английский
Процитировано
1
Pharmacological Research, Год журнала: 2024, Номер unknown, С. 107420 - 107420
Опубликована: Сен. 1, 2024
Endometrial cancer (EC) is one of the most common gynecologic malignancies, which lacking effective drugs for intractable conditions or patients unsuitable surgeries. Recently, patient-derived organoids (PDOs) are found feasible research and drug discoveries. Here, we established a series PDOs from EC performed repurposing screening mechanism analysis treatment. We confirmed that regulatory β subunit methionine adenosyltransferase (MAT2B) highly correlated with malignant progression in endometrial cancer. Through on PDOs, identify JX24120, chlorpromazine derivative, as specific inhibitor MAT2B, directly binds to MAT2B (K
Язык: Английский
Процитировано
1
Cytotechnology, Год журнала: 2024, Номер 76(5), С. 571 - 584
Опубликована: Июнь 24, 2024
Язык: Английский
Процитировано
0